RightFit
RecruitingNot applicable

The Glaucoma and Retinopathy Screening Study

The Glaucoma and Retinopathy Screening Study (GRaSS)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
40 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests a new way to screen for glaucoma, an eye disease that can harm vision. It uses artificial intelligence (AI) to read photos of the back of the eye, checks eye pressure, and tests side vision with a headset if needed. It is for people with diabetes who are getting AI-based eye screening at primary care centers.

The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma. Participants will: Have an image of their fundus (back of the eye) taken as part of their diabetic eye screening Have a measurement of their eye pressure If needed, have a test of their side vision using a headset

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Have diabetes and be getting screened for diabetic retinopathy (eye damage from diabetes) at a primary care center using the LumineticsCore AI system.
  • Be able and willing to give informed consent, meaning you understand the study and agree to take part.

Who can't join

    Simplified for readability. The official criteria below are what the study team uses.

    Official eligibility criteria

    * Individuals with diabetes undergoing AI-based screening for diabetic retinopathy using the LumineticsCore (Digital Diagnostics) system at primary care centers. * Individuals who are able and willing to provide informed consent for participation in the study.

    Study sites (7)

    MA